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Multiple endocrine neoplasia type 1 (MEN1), the
heritable tendency to develop tumors of the parathyroid,
pituitary, and entero-pancreatic endocrine tissues, is
the consequence of a germline mutation in the MEN1
gene. Endocrine tumors in these patients result when
the mutant MEN1 allele is accompanied by loss of the
normal MEN1 allele. Recently it was reported that
MEN1 patients also exhibit several cutaneous tumors,
including multiple angiofibromas, collagenomas, and
lipomas. The purpose of this study was to examine
skin lesions from patients with MEN1 for allelic loss
of the MEN1 gene. Skin lesions from five patients
Multiple endocrine neoplasia type 1 (MEN1) is adominantly inherited tumor syndrome in whichpatients characteristically develop tumors of para-thyroid glands, entero-pancreatic endocrine tissue,and anterior pituitary (Metz et al, 1994). The
tendency to develop these tumors results from mutations in a tumor
suppressor gene. The MEN1 gene, known for several years to reside
on the long arm of chromosome 11 (Larsson et al, 1988), was recently
cloned (Chandrasekharappa et al, 1997). Mutations in this gene have
been reported in 47 kindreds (Agarwal et al, 1997).
Tumor suppressor genes are so named because their functional
absence leads to the formation of tumors. Because there are two copies
of each autosomal gene, both alleles must be inactivated for tumors to
develop (the Knudson ‘‘two-hit’’ hypothesis) (Knudson, 1985). In the
case of inherited cancer syndromes, one allele is inactivated through a
germline mutation. A somatic mutation in the second allele then leads
to the formation of a tumor. It has been observed that this ‘‘second
hit’’ is commonly a large deletion, encompassing the normal gene
along with its flanking DNA (Dong et al, 1997). Prior to the
identification of a gene, the loss of the gene may be suggested by the
loss of polymorphic markers flanking a candidate region. In these
studies, normal tissue shows two alleles and the tumor shows only one
allele, a finding referred to as loss of heterozygosity (LOH). LOH of
polymorphic markers flanking the MEN1 gene was demonstrated for
several tumors in MEN1 (Dong et al, 1997, and references therein).
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with MEN1 were examined using fluorescence in situ
hybridization. Six angiofibromas, three collagenomas,
and one lipoma showed allelic deletion of the MEN1
gene. Allelic deletion was not observed in a melanocytic
nevus or acrochordon from patients with MEN1. It
was also not observed in an angiofibroma from a
patient with tuberous sclerosis. These results suggest
that loss of function of the wild-type MEN1 gene product
plays a role in the development of angiofibromas,
collagenomas, and lipomas in patients with MEN1.
Key words: angiofibroma/collagenoma/FISH/lipoma/tumor
suppressor gene. J Invest Dermatol 110:438–440, 1998
Once the gene is identified, however, the deletion of the normal allele
can be observed directly by fluorescence in situ hybridization (FISH).
Thus one may examine individual nuclei for hybridization of a
fluorescent probe to each allele of the MEN1 gene. The presence of
only one signal indicates the loss of that gene in the cell. This technique
has been used to show allelic deletions at the MEN1 gene locus in
gastrinomas and insulinomas (Zhuang et al, 1997).
Recently, we found that patients with MEN1 have the tendency to
develop cutaneous tumors including multiple facial angiofibromas
[previously considered pathognomonic for tuberous sclerosis (TS)] and
collagenomas (Darling et al, 1997), in addition to the previously noted
lipomas (Ballard et al, 1964). The occurrence of these skin lesions
raised the question of whether they were a consequence of a ‘‘second
hit,’’ or secondary to other factors such as haploinsufficiency. Here we
show that facial angiofibromas, collagenomas, and lipomas show allelic
deletion of the MEN1 gene.
MATERIALS AND METHODS
Patients Five patients with MEN1 were evaluated in this study. Four are
familial cases from large MEN1 kindreds and one case (patient 4) is sporadic,
suspected to have a de novo mutation. Their ages ranged from 16 y (the youngest
MEN1 patient with angiofibromas documented to date) to 69 y (Table I). All
of these individuals (patients 1–5) had five or more facial angiofibromas, and
all but patient 1 had multiple collagenomas and single or multiple cutaneous
lipomas. The cutaneous findings of two patients were reported previously
[patients 4 and 5 in this study correspond to patients 27 and 31, respectively,
in Darling et al (1997)]. The diagnosis of MEN1 was as previously defined
(Darling et al, 1997). In addition, all five individuals have known mutations in
the MEN1 gene (Table I) (Chandrasekharappa et al, 1997; Agarwal et al, 1997).
Two control patients without MEN1 were also examined, control 1 with TS
and control 2 with sporadic primary hyperparathyroidism.
Fluorescence in situ hybridization Touch preparations of fresh tissue were
made at the time of biopsy. Prior to the touch preparation, tissue specimens
were blotted of blood, bisected as needed to expose the tumor, and care was
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Table I. Patients with MEN1 show allelic deletion of the MEN1 gene in angiofibromas, collagenomas, and lipomas
Skin lesions with allelic deletion by FISH Skin lesions without allelic deletion by FISH
% Cells with one
signal for MEN1 % Cells with one signal
MEN1 germline Histologic probe (total # cells for MEN1 probe
#/age/sex Disease mutationa diagnosis scored) Histologic diagnosis (total # cells scored)
Patients
1/16/M MEN1 R460X Angiofibroma 63.3 (120)
2/42/F MEN1 Y323X Angiofibroma 48.0 (100)
Angiofibroma 52.4 (82)
3/46/F MEN1 713delG Collagenoma 65.3 (95) Melanocytic nevus 3.3 (91)
Collagenoma 68.5 (73)
4/56/F MEN1 Q260X Angiofibroma 63.5 (63)b
Angiofibroma
5/69/M MEN1 W436R Angiofibroma 59.5 (84)
Collagenoma 62.5 (48) Acrochordon 7.1 (84)
Lipoma 54.5 (66)
Controls
1/38/F Tuberous sclerosis NAc Angiofibroma 4.4 (91)
2/54/F Sporadic primary NA Melanocytic nevus 7.1 (85)
hyperparathyroidism Melanocytic nevus 8.7 (50)
(not MEN1) Melanocytic nevus 2.3 (87)
aChandrasekharappa et al, 1997; Agarwal et al, 1997.
bBecause of the low (yet comparable) numbers of cells present, the data for these two angiofibromas are combined.
cNA, not applicable.
taken to touch mostly tumor to the slide (dermis for angiofibromas and
collagenomas, and fat for lipoma). The tissue was then placed in formalin and
processed for light microscopy. Touch preparations were used for FISH analysis
as described previously (Pinkel et al, 1986; Ried et al, 1993). In brief, a cosmid
clone c10B11 (size 40 kb) containing the MEN1 gene was used as a red-signal
probe (Guru et al, 1997). An alpha-satellite centromeric marker for chromosome
11 was used as a green-signal control. Hybridization signals were scored using
a Zeiss (Thornwood, NY) Axiophot epifluorescence microscope and two-color
images were captured on a Photometrics CCD camera (Photometrics, Tucson,
AZ) using IP Lab image software (Signal Analytics, Vienna, VA). In normal
cells, less than 11% of nuclei show only one signal, in part due to overlapping
of two signals (Anastasi et al, 1990). The presence of more than 30% of cells
with only one MEN1 signal was interpreted as allelic deletion (Zhuang
et al, 1997).
RESULTS AND DISCUSSION
Angiofibromas in patients with MEN1 show allelic deletion of
the MEN1 gene Six facial angiofibromas from five patients with
MEN1 were analyzed using FISH. All angiofibromas showed allelic
deletion of the MEN1 gene (Table I, Fig 1). The percentage of cells
with only one signal per nucleus for the MEN1 probe ranged from
48 to 64%. In some cases, there was also loss of the centromeric
marker, suggesting loss of the entire chromosome 11. For controls,
two of the patients with MEN1 had FISH analysis of benign skin
lesions not associated with MEN1 disease. A melanocytic nevus and
an acrochordon did not exhibit allelic deletion of the MEN1 gene,
showing two signals per nucleus for the MEN1 probe in 97 and 93%
of cells, respectively. Thus, it appears that allelic deletion of MEN1
plays a role in the development of angiofibromas in patients with
MEN1, but not in other skin lesions that are common to the general
population. It should be noted that we have not formally proven that
the observed deletion involved the wild-type MEN1 allele. It is
remotely possible that the deletion eliminated the mutant copy of the
MEN1 gene or even a different tumor suppressor gene adjacent to the
MEN1 gene. Very different methods (e.g., allele specific polymerase
chain reaction on single cells) would be required to exclude these
unlikely mechanisms.
Angiofibromas are also seen in TS. Only 4% of the cells from a TS
angiofibroma showed a single signal for the MEN1 probe (Table I).
Presumably, this lesion instead possessed deletions in one of the TS
genes, as reported previously for cutaneous fibromas from patients with
TSC2 (Sepp et al, 1996). These data indicate that these identically
appearing lesions can arise as a consequence of the loss of distinct
tumor suppressor genes involved in entirely different syndromes.
Collagenomas and a lipoma in patients with MEN1 show allelic
deletion of the MEN1 gene Three collagenomas from two patients
with MEN1 were evaluated for allelic deletion. The percentage of
cells with one signal for the MEN1 probe ranged from 63 to 68% in
touch preparations of these tumors (Table I, Fig 1), indicating that
loss of MEN1 gene function also plays a role in the development of
collagenomas. Lastly, a lipoma from one patient with MEN1 showed
allelic loss of the MEN1 gene (54%) (Table I). This confirms earlier
studies of lipomas in patients with MEN1, which demonstrated LOH
at 11q13 in two lipomas, one of which was a large visceral lipoma
(Morelli et al, 1995; Dong et al, 1997).
Melanocytic nevi in a patient with sporadic primary hyperpara-
thyroidism do not show allelic deletion of the MEN1 gene A
patient with sporadic primary hyperparathyroidism had multiple dermal
melanocytic nevi (control 2). Touch preps of three of these nevi were
analyzed for allelic deletion of the MEN1 gene, providing additional
controls for hybridization efficiency in normal cells. In 91–98% of the
cells, two signals for the MEN1 probe were evident. In summary,
control tissues showed one signal per nucleus in 5.5% 6 2.5% of cells
(mean 6 SD, n 5 6). The presence of one signal in these nuclei is
unlikely to represent the spontaneous deletion of one MEN1 allele
and probably represents insufficient hybridization. A similar low
percentage of normal cells showing single-signal hybridization was
obtained in a previous FISH study (Anastasi et al, 1990). The data for
control tissues in this study were used to establish an upper limit of
normal, using two standard deviations above the mean as a boundary.
Thus the observation of less than 11% of nuclei with a single signal
for the MEN1 probe is within the range of normal. For comparison,
no fewer than 48% of cells showed a single signal for the MEN1 probe
in the tissues with allelic deletion.
Implications of allelic deletion in cutaneous tumors These
findings suggest that angiofibromas, collagenomas, and lipomas in
patients with MEN1 are benign neoplasms of a mono- or oligoclonal
nature. Accordingly, a cell with a germline mutation on one MEN1
allele loses the normal MEN1 allele, leading to abnormal proliferation
of this cell. It is not yet clear which cell population is involved in
this genetic alteration in angiofibromas, because angiofibromas are
hamartomas showing increased numbers of several cell types (Benjamin,
1996). This cell heterogeneity contributes to the difficulty in demon-
strating a ‘‘second hit’’ in these lesions. A prior study of three
angiofibromas in patients with MEN1 was unable to demonstrate LOH
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Figure 1. Cutaneous angiofibromas and collagenomas in patients with
MEN1 show allelic deletion of the MEN1 gene. (A) Discrete papules are
evident on the left of the nose of patient 5, including the lesion chosen for
biopsy as indicated by the arrow. (B) Light microscopy of this lesion shows
concentric layers of collagen around vessels and a hair follicle, as seen in
angiofibromas. Scale bar, 100 µm. (C) FISH analysis of a touch preparation of
this angiofibroma shows allelic deletion of the MEN1 gene (red signal) in three
nuclei, but the presence of both alleles for the centromeric marker (in green).
Scale bar, 5 µm. (D) On the right shoulder of patient 5 are two dome-shaped
papules, including the lesion biopsied as indicated by the arrow. (E) Light
microscopy of this lesion revealed a widened dermis composed of thickened
collagen in a haphazard array characteristic of collagenoma. Scale bar, 1.0 mm.
(F) FISH analysis of a touch preparation of this collagenoma demonstrated
allelic deletion of the MEN1 gene (red signal) in six of 10 nuclei. Scale bar, 5 µm.
at 11q13 (Dong et al, 1997). The ability to show allelic deletion in
this study illustrates the utility of FISH in evaluating the genetic
makeup of individual tumor cells interspersed amongst other cellular
constituents. Further studies are in progress to determine which cell
type shows allelic deletion.
Patients with MEN1 can exhibit combinations of multiple angiofib-
romas, collagenomas, and lipomas. By FISH analysis we have demon-
strated that two separate angiofibromas in one patient can show allelic
deletion of the MEN1 gene, and that different skin lesions in one
patient can show allelic deletion. Allelic deletion in each lesion
presumably arises by independent ‘‘second hits,’’ as is the case for the
multiple endocrine tumors in patients with MEN1 (Lubensky et al,
1996). Furthermore, the second hit is a random occurrence, suggesting
that skin lesions should be randomly distributed. This appears to be
the case for lipomas in patients with MEN1, and also for neurofibromas
in patients with neurofibromatosis, an inherited tumor syndrome in
which neurofibromas show LOH for the NF1 gene (Colman et al,
1995). Angiofibromas, in both patients with MEN1 and patients
with TS, however, predominate on the central face. This localized
distribution suggests that additional factors besides allelic loss control
whether an angiofibroma may develop. Exposure to ultraviolet light
is one possible factor for these lesions on the central face, but ultraviolet
light is not characteristically associated with large deletions. It seems
more likely that the skin of the central face is sufficiently different
from other body sites to facilitate the formation of angiofibromas more
easily. This is analogous to the problem of why tumor suppressor
genes, widely expressed in different tissues of the body, when inactiv-
ated, promote tumor formation in specific organs and not others. With
angiofibromas, it is apparent that this specificity extends even to a
location within an organ.
We thank Dr. Allen Spiegel for his support, and we thank members of the NIH
Interinstitute Endocrine Program for clinical contributions. We thank Harry Schaefer for
preparing the illustration and David Ault for technical assistance.
REFERENCES
Agarwal SK, Kester MB, Debelenko LV, et al: Germline mutations of the MEN1 gene in
familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet
7:1169–1175, 1997
Anastasi J, LeBeau MM, Vardiman JW, Westbrook CA: Detection of numerical
chromosomal abnormalities in neoplastic hematopoietic cells by in situ hybridization
with a chromosome- specific probe. Am J Pathol 136:131–139, 1990
Ballard HS, Frame B, Hartsock RJ: Familial multiple endocrine adenoma-peptic ulcer
complex. Med 43:481–512, 1964
Benjamin DR: Cellular composition of the angiofibromas in tuberous sclerosis. Pediatr
Pathol Lab Med 16:893–899, 1996
Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for
multiple endocrine neoplasia-type 1. Science 276:404–407, 1997
Colman SD, Williams CA, Wallace MR: Benign neurofibromas in type 1 neurofibromatosis
(NF1) show somatic deletions of the NF1 gene. Nature Genet 11:90–92, 1995
Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M: Multiple facial
angiofibromas and collagenomas in patients with multiple endocrine neoplasia type
1. Arch Dermatol 133:853–857, 1997
Dong Q, Debelenko LV, Chandrasekharappa SC, et al: Loss of heterozygosity at 11q13:
analysis of pituitary tumors, lung carcinoids, lipomas and other uncommon tumors
in subjects with familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab
82:1416–1420, 1997
Guru SC, Olufemi SE, Manickam P, et al: A 2.8-Mb clone contig of the multiple endocrine
neoplasia type-1 (MEN1) region at 11q13. Genomics 42:436–445, 1997
Knudson AG: Hereditary cancer, oncogenes and antioncogenes. Cancer Res 45:1437–
1443, 1985
Larsson C, Skogreid B, Oberg K, Nakamura Y, Nordenskjold M: Multiple endocrine
neoplasia type 1 gene maps to chromosome 11 and is lost in insulinomas. Nature
332:85–87, 1988
Lubensky IA, Debelenko LV, Zhuang Z, et al: Allelic deletions on chromosome 11q13 in
multiple tumors from individual MEN1 patients. Cancer Res 56:5272–5278, 1996
Metz DC, Jensen RT, Bale A, et al: Multiple endocrine neoplasia type 1: Clinical features
and management. In: Bilezekian JP, Levine MA, Marcus R (eds). The Parathyroids.
Raven Press, New York, 1994, pp. 591–646
Morelli A, Falchetti A, Weinstein L, et al: RFLP analysis of human chromosome 11 region
q13 in multiple symmetric lipomatosis and multiple endocrine neoplasia type 1-
associated lipomas. Biochem Biophys Res Commun 207:363–368, 1995
Pinkel D, Straune T, Gray JW: Cytogenetic analysis using quantitative, high sensitivity
fluorescence hybridization. Proc Natl Acad Sci USA 83:2934–2938, 1986
Ried T, Lengauer C, Lipp M, Fischer C, Cremer T, Ward DC: Evaluation of the utility
of interphase cytogenetics to detect residual cells with a malignant genotype in
mixed cell populations: a Burkitt lymphoma model. DNA Cell Biol 12:637–643, 1993
Sepp T, Yates JRW, Green AJ: Loss of heterozygosity in tuberous sclerosis hamartomas.
J Med Genet 33:962–964, 1996
Zhuang Z, Vortmeyer AO, Pack S, et al: Somatic mutations of the MEN1 tumor suppressor
gene in sporadic gastrinomas and insulinomas. Can Res 57:4682–4686, 1997
